Follow
Engineering T cells
Engineering T cells is a broad description of techniques used to modify a T cells obtained from a patient or healthy donor. T cells are a subset of immune cells responsible for targeting and killing tumor cells. Once harvested from a patient or donor, the T cells can be engineered in a laboratory making them better capable of killing a specific tumor. Examples of adoptive cell therapies using engineered T cells are T cell receptor (TCR)-engineered T cells and chimeric antigen receptor (CAR) T cells.
FEB 23, 2022 | 3:00 PM
Genetically engineered cellular models are an integral part of the drug discovery process from early discovery through clinical biomanufacturing. The various applications of these cellular m...
DEC 09, 2021 | 8:00 AM
Date: December 9, 2021 Time: 8:00am (PDT), 11:00am (EDT) Engineering human regulatory T cells (Tregs) with a chimeric antigen receptor (CAR) targeting donorderived human leukocyte antigen (H...
DEC 07, 2021 | 8:00 AM
Date: November 7, 2021 Time: 8:00am (PDT), 11:00am (EDT) Analysis of SARS-CoV-2–specific T cells is important to understand their role during acute disease and in long-term protection...
NOV 18, 2021 | 8:00 AM
Date: November 18, 2021 Time: 8:00am (PDT), 11:00am (EDT) Keep ahead in CAR T and CAR NK cell research. We introduce advanced techniques for generating and characterizing engineered immune c...
NOV 04, 2021 | 8:00 AM
Date: November 4, 2021 Time: 8:00am (PDT), 11:00am (EDT) The promise of tissue clearing techniques in combination with 3D-immunofluorescence (IF) microscopy is revolutionary. Complex biologi...
OCT 28, 2021 | 7:00 AM
Date: September 16, 2021 Time: 7:00am (PDT), 10:00am (EDT) High-dimensional flow cytometry generates a wealth of data. Computational approaches can help to simplify the complexity of large d...
OCT 12, 2021 | 8:00 AM
Date: October 12, 2021 Time: 8:00am (PDT), 11:00am (EDT) CRISPR-Cas9 is a nuclease-based genome editing system which has seen exponential growth in adoption with broad applications from basi...
OCT 07, 2021 | 11:55 PM
Summary: Cancer neoantigens are highly specific to the tumor, potently immunogenic and can be targeted by both vaccines and engineered cellular therapies. This talk will introduce the defini...
SEP 22, 2021 | 11:59 PM
T cells exquisitely discriminate between antigenic and self-peptide ligands presented on major histocompatibility complexes (pMHCs) despite subtle differences in affinities. This aspect of a...
SEP 08, 2021 | 9:00 AM
Date: September 8, 2021 Time: 9:00am (PDT), 12:00pm (EDT) Implanted biomedical devices comprise a major component of modern medicine and are essential for many clinical applications ranging...
AUG 26, 2021 | 8:00 AM
Date: August 26, 2021 Time: 8:00am (PDT), 11:00am (EDT) My translational research program focuses on approaches to enhance the natural killer (NK) cell response to cancer, with an emphasis o...
AUG 26, 2021 | 7:00 AM
Date: August 26, 2021 Time: 7:00am (PDT), 10:00am (EDT) Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with rising incidence and a remarkable resistance to current therapies. In t...
JUL 22, 2021 | 5:00 PM
Though tumor targeting using chimeric receptors (CAR) engineered to bind tumor-associated surface proteins such as CD19 in B cells have demonstrated remarkable efficacy in cancer, this thera...
JUL 22, 2021 | 4:15 PM
Genome editing technologies have enabled the precise manipulation of DNA sequences at targeted sites to achieve therapeutic effects. Engineered endonucleases like CRISPR-Cas9 institute site-...
JUL 22, 2021 | 12:45 PM
Gene editing technologies such as CRISPR/Cas9 have greater flexibility and high efficiency. CRISPR technology enables targeted insertion of transgenes at the desired locus and has the abilit...
JUL 22, 2021 | 12:45 PM
Though AsCas12a fills a crucial gap in the current genome editing toolbox, it exhibits relatively poor editing efficiency, restricting its overall utility. In collaboration with Integrated D...
